"PTK6 Inhibitors May Target Endocrine Therapy-Resistant ER+ Breast Cancer"
Interview with Hanna Irie, MD, PhD, senior author and assistant professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai and a medical oncologist at the Dubin Breast Center at The Mount Sinai Hospital answers several questions regarding ER+ breast cancer. Dr. Irie shares, “Additional studies validating PTK6 as a therapeutic target for ER+ breast cancer, the most common breast cancer subtype, are underway and could lead to a novel approach to treating these cancers.”
- Hanna Irie, MD, PhD, Assistant Professor, Medicine, Hematology and Medical Oncology, Oncological Services, Icahn School of Medicine at Mount Sinai, Medical Oncologist, Dubin Breast Center, The Mount Sinai Hospital